- Home
- ENTA vs GPRK Comparison
ENTA vs GPRK Comparison
Compare ENTA & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTA | GPRK |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.3M | 397.8M |
| IPO Year | 2012 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ENTA | GPRK |
|---|---|---|
| Price | $12.70 | $8.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $20.40 | $8.50 |
| AVG Volume (30 Days) | 155.3K | ★ 724.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $5.91 | N/A |
| Revenue Next Year | N/A | $23.25 |
| P/E Ratio | ★ N/A | $12.70 |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $4.09 | $5.66 |
| 52 Week High | $17.15 | $9.09 |
Technical Indicators
Market Signals| Indicator | ENTA | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 57.96 |
| Support Level | $12.09 | $7.84 |
| Resistance Level | $15.52 | $9.09 |
| Average True Range (ATR) | 0.81 | 0.37 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 4.86 | 69.10 |
Price Performance
Historical ComparisonAbout ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.